Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for GBLX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
December 31, 2024 -0.1243M
September 30, 2024 -0.1077M
June 30, 2024 -0.022M
March 31, 2024 -0.2525M
December 31, 2023 -0.2054M
September 30, 2023 -0.4125M
June 30, 2023 -0.1053M
March 31, 2023 -0.2199M
December 31, 2022 -0.3994M
September 30, 2022 -0.6155M
June 30, 2022 -0.292M
March 31, 2022 -0.6652M
December 31, 2021 -0.4285M
September 30, 2021 -0.1359M
June 30, 2021 -0.6366M
March 31, 2021 -0.932M
December 31, 2020 -1.040M
September 30, 2020 0.111M
June 30, 2020 -0.3238M
March 31, 2020 -0.2314M
December 31, 2019 -2.46M
September 30, 2019 0.8428M
June 30, 2019 -2.631M
March 31, 2019 -2.008M
December 31, 2018 -1.464M
Date Value
September 30, 2018 -2.888M
June 30, 2018 -3.496M
March 31, 2018 -4.226M
December 31, 2017 -2.771M
September 30, 2017 -3.061M
June 30, 2017 -2.190M
March 31, 2017 -1.628M
December 31, 2016 -1.148M
September 30, 2016 -0.7354M
June 30, 2016 -0.9579M
March 31, 2016 -0.7019M
December 31, 2015 -1.296M
September 30, 2015 -0.4789M
June 30, 2015 -1.087M
March 31, 2015 -0.2308M
December 31, 2014 -0.8695M
September 30, 2014 -1.507M
June 30, 2014 -0.9388M
March 31, 2014 -0.1803M
December 31, 2013 -0.005M
September 30, 2013 -0.0175M
June 30, 2013 -0.0109M
March 31, 2013 -0.0011M
December 31, 2012 -0.0112M
September 30, 2012 -0.023M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Cocrystal Pharma, Inc. -2.536M
CNBX Pharmaceuticals, Inc. -0.0477M
Arvinas, Inc. -48.30M
Fulcrum Therapeutics, Inc. -16.04M
Definium Therapeutics, Inc. -52.33M